Rocket Pharmaceuticals (RCKT) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Vanda Pharmaceuticals (VNDA) has outperformed Rocket Pharmaceuticals (RCKT) over the past year, losing 16.1% versus a loss of 30.2%. Over five years, VNDA leads with a -75.2% price change compared with -90.8% for RCKT. Rocket Pharmaceuticals is the larger company by market cap ($281.0 million vs $276.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RCKT | VNDA |
|---|---|---|
| Share price | $2.56 | $4.57 |
| Market cap | $281.02M | $276.31M |
| 1-day change | -2.66% | +0.88% |
| YTD return | -27.07% | -48.19% |
| 1-year return | -30.25% | -16.15% |
| 5-year return | -90.83% | -75.18% |
| Forward P/E | — | 22.85 |
| EPS (TTM) | $-0.17 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $9.94 |
| 52-week low | $2.42 | $4.27 |
| Distance from 52-week high | -53.03% | -54.02% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +232.03% | +157.11% |
| Average volume | 1.67M | 980.33K |
| Shares outstanding | 109.77M | 60.46M |
| Employees | 202 | 533 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VNDA has outperformed RCKT by 14.1 percentage points over the past year.
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
RCKT vs VNDA FAQ
Which is bigger, Rocket Pharmaceuticals or Vanda Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) is larger, with a market capitalization of $281.02M compared with $276.31M for Vanda Pharmaceuticals (VNDA).
Which stock has performed better over the past year, RCKT or VNDA?
VNDA returned -16.15% over the past 12 months, compared with -30.25% for RCKT (price return, excluding dividends). Past performance does not predict future results.
Are Rocket Pharmaceuticals and Vanda Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.